Immediate Impact
35 standout
Citing Papers
Bispecific antibodies: advancing precision oncology
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Works of Laura París being referenced
CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
2023
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Laura París | 22 | 31 | 21 | 53 | 24 | 21 | 149 | |
| Sue Dean | 42 | 19 | 56 | 37 | 26 | 23 | 210 | |
| Beverley Anne Yamamoto | 10 | 9 | 62 | 7 | 55 | 28 | 190 | |
| Amarjit Singh Sethi | 16 | 47 | 23 | 12 | 4 | 20 | 134 | |
| Thomas Cole | 43 | 10 | 7 | 7 | 4 | 27 | 250 | |
| Laura Beck | 32 | 20 | 40 | 10 | 20 | 224 | ||
| Μαρία Σακελλαρίου | 19 | 13 | 50 | 29 | 32 | 242 | ||
| Sarah O’Sullivan | 25 | 41 | 20 | 22 | 12 | 172 | ||
| Erika P. New | 2 | 98 | 4 | 26 | 48 | 20 | 169 | |
| Manusheela Pokharel | 23 | 41 | 9 | 32 | 26 | 246 | ||
| Constantin‐Cristian Topriceanu | 1 | 4 | 31 | 20 | 12 | 19 | 184 |
All Works
Login with ORCID to disown or claim papers
Loading papers...